J
Jason Dungu
Researcher at St George's, University of London
Publications - 39
Citations - 1420
Jason Dungu is an academic researcher from St George's, University of London. The author has contributed to research in topics: Cardiac amyloidosis & Heart failure. The author has an hindex of 11, co-authored 31 publications receiving 1085 citations. Previous affiliations of Jason Dungu include St George's Hospital & Basildon and Thurrock University Hospitals NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial
Brian P Halliday,Rebecca Wassall,Amrit Lota,Zohya Khalique,John Gregson,Simon Newsome,Robert B. Jackson,Tsveta Rahneva,Rick Wage,Gillian Smith,Lucia Venneri,Upasana Tayal,Dominique Auger,William Midwinter,Nicola Whiffin,Nicola Whiffin,Ronak Rajani,Jason Dungu,Antonis Pantazis,Stuart A. Cook,James S. Ware,James S. Ware,A. John Baksi,Dudley J. Pennell,Stuart D. Rosen,Stuart D. Rosen,Martin R. Cowie,John G.F. Cleland,John G.F. Cleland,Sanjay K Prasad +29 more
TL;DR: Many patients deemed to have recovered from dilated cardiomyopathy will relapse following treatment withdrawal, and until robust predictors of relapse are defined, treatment should continue indefinitely.
Journal ArticleDOI
Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome
Jennifer H. Pinney,Carol J. Whelan,Aviva Petrie,Jason Dungu,Jason Dungu,Sanjay M Banypersad,Sanjay M Banypersad,Prayman T. Sattianayagam,Ashutosh D. Wechalekar,Simon D. J. Gibbs,Christopher P. Venner,Nancy Wassef,Carolyn A. McCarthy,Janet A. Gilbertson,Dorota Rowczenio,Philip N. Hawkins,Julian D. Gillmore,Helen J. Lachmann +17 more
TL;DR: Factors at baseline associated with a worse outcome in ATTRwt are positive troponin T, a pacemaker, and NYHA class IV symptoms, and the age of the patient at diagnosis and NT pro‐BNP level can aid in distinguishing AT TRwt from AL amyloidosis.
Journal ArticleDOI
CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis
Jason Dungu,Oswaldo Valencia,Jennifer H. Pinney,Simon D. J. Gibbs,Dorota Rowczenio,Janet A. Gilbertson,Helen J. Lachmann,Ashutosh D. Wechalekar,Julian D. Gillmore,Carol J. Whelan,Philip N. Hawkins,Lisa J. Anderson +11 more
TL;DR: Transmural patterns of LGE distinguished ATTR from AL cardiac amyloidosis with high accuracy in this real-world analysis of CMR.
Journal ArticleDOI
Systemic Amyloidosis in England: an epidemiological study
Jennifer H. Pinney,Colette J. Smith,Jessi B. Taube,Helen J. Lachmann,Christopher P. Venner,Simon D. J. Gibbs,Jason Dungu,Sanjay M Banypersad,Ashutosh D. Wechalekar,Carol J. Whelan,Philip N. Hawkins,Julian D. Gillmore +11 more
TL;DR: The available data suggest the incidence of systemic amyloidosis in England exceeds 0·8/100 000 of the population, although there are various limitations to this study.
Journal ArticleDOI
Cardiac transthyretin amyloidosis
TL;DR: The clinical features of cardiac ATTR amyloidosis are reviewed and the diagnostic tests to determine ATTR type are described, which have a poorer prognosis and can be amenable to chemotherapy.